Prot# XL999-203: A Phase 2 Study of XL999 Administered Intravenously to Subjects with Relapsed/Refractory Multiple Myeloma

    Project: Research project

    Project Details

    StatusFinished
    Effective start/end date8/23/068/23/09

    Funding

    • National Cancer Institute (R01 CA125077)